Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma

College athletes rarely develop heart problems one year after having COVID-19
12 May 2022
Protein related to Fragile X syndrome may be a new target for blood pressure medicines
12 May 2022

Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma

A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy). The study is published in Cancer Discovery.

Comments are closed.